Recent advancements in diabetes therapeutics introduced several novel agents and delivery platforms in human medicine, including long-acting insulin analogs, GLP-1 receptor agonists, and SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and diabetes mellitus.